Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines Immunotherapy
Scientists at Herlev University, Department of Hematology publish research in cancer vaccines immunotherapy
November 18th, 2008
Scientists discuss in 'RhoC a new target for therapeutic vaccination against metastatic cancer' new findings in cancer vaccines. "Most cancer deaths are due to the development of metastases. Increased expression of RhoC is linked to enhanced metastatic potential in multiple cancers," scientists writing in the journal Cancer Immunology, Immunotherapy report. "Consequently, the RhoC protein is an attractive target for drug design. The clinical application of immunotherapy against cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of 'therapeutic' vaccines. The over-expression of RhoC in...
Source: Cancer Weekly (2008-11-18)
|
